Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > BUSINESS
BUSINESS
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
- Takeda’s 3 Nesina Family Drugs Make US Debut
June 19, 2013
- MSD to Continue Efforts for HPV Vaccine Recommendation
June 19, 2013
- Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
- Chairman Kato Resigns, to Move to Specially Appointed Professor Position at University of Tokyo: AZ
June 19, 2013
- GSK Says No Evidence Shows Causal Link between HPV Vaccines and Serious Adverse Events
June 18, 2013
- Shionogi Signs MOU on R&D with Six Universities in Ireland
June 18, 2013
- Eisai to Expand Packaging Facility at UK Plant, Eying Lenvatinib Launch
June 18, 2013
- Takeda, Pfizer Settle Protonix Patent Lawsuit with Teva, Sun for US$2.15 Billion
June 17, 2013
- Stroke Prevention Effects Confirmed in PIII Study of Pradaxa in Asia: BI Japan
June 17, 2013
- Daiichi Sankyo, JICA Start Technical Cooperation on MR Vaccine Production in Vietnam
June 17, 2013
- Sanofi Ends Development on Iniparib, Otamixaban
June 14, 2013
- ARBs Still Best Sellers in FY2012 Sales Ranking, Januvia Ranks in Top 10 after only 3 Years of Launch
June 14, 2013
- Nippon Shinyaku’s Licensee Taejoon Pharm Launches Gaslon N-OD Tablets in South Korea
June 14, 2013
- AbbVie, Meiji Seika Pharma Start PIII of Fluvoxamine for Pediatric OCD
June 14, 2013
- SGLT-2 Inhibitors Being Submitted for Marketing Authorization; First of 6 APIs Should Debut Next Spring
June 14, 2013
- Daiichi Sankyo Launches Osteoporosis Treatment Pralia
June 13, 2013
- Domestic Sales of OTC Drugs Expected to Reach 607.2 Billion Yen in 2013: Fuji-Keizai
June 13, 2013
- DSP, Shionogi Launch Avapro, Irbetan Tablets 200 mg
June 13, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…